WEREWOLF THERAPEUTICS, INC. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of May 29, 2020, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and WEREWOLF THERAPEUTICS, INC. (collectively with each of the other Persons, if any, that join as a co-Borrower hereunder are collectively referred to as the “Borrowers” and individually as a “Borrower”).
WEREWOLF THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT DECEMBER 23, 2020Investors’ Rights Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 23rd day of December, 2020, by and among Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
WEREWOLF THERAPEUTICS, INC. STOCK OPTION AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLANStock Option Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations
This Stock Option Agreement (this “Agreement”) is made between Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), and the Participant pursuant to the 2017 Stock Incentive Plan (the “Plan”).
AMENDED AND RESTATED ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Royalty Transfer Agreement (the “Agreement”) is made and entered into on August 2, 2019 (the “Effective Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), MPM Oncology Impact Fund Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, the “Charitable Foundations”).
WEREWOLF THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLANRestricted Stock Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 20[ ], between Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Participant”).
LEASE CAMBRIDGE 1030 MASS AVE, LLC a Delaware limited liability company as Landlord, and WEREWOLF THERAPEUTICS, INC. a Delaware corporation as Tenant.Massachusetts Avenue • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between Cambridge 1030 Mass Ave, LLC, a Delaware limited liability company (“Landlord”), and Werewolf Therapeutics, Inc., a Delaware corporation (“Tenant”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SECOND AMENDED AND RESTATED...And License Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • California
This Second Amended and Restated Assignment and License Agreement (this “Agreement”) is entered into as of December 20, 2019 (the “Second Amendment Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation, with a place of business at 1030 Massachusetts Avenue, 2nd Floor, Cambridge, MA 02138 (“Werewolf”), and Harpoon Therapeutics, Inc., a Delaware corporation with a place of business at 4000 Shoreline Court, Suite 250, South San Francisco, CA 94080 (“Harpoon”).
